Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA

NCT00369122 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00369122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00369122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 11, 2006
Completion date
December 15, 2016
Enrollment
60 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, not otherwise specified, stage ib cervical cancer ajcc v6 and v7, stage iia cervical cancer ajcc v7, stage iib cervical cancer ajcc v6 and v7, stage iii cervical cancer ajcc v6 and v7